患者发起随访联合异步远程医疗与常规照护在脊柱关节炎中的比较(TeleSpA研究):一项评估临床与成本效果的随机对照试验
TeleSpA为多中心、实用、开放标签随机对照试验,纳入200例病情稳定的脊柱关节炎患者,1:1分配至患者发起随访联合异步远程医疗组或常规照护组。1年内风湿科就诊次数平均为1.9次(SD 1.5) vs 2.6次(SD 1.3),平均差-0.7(95%CI -1.0至-0.3),降低25.4%,p<0.0001;从医疗保健角度具有成本效果,节省医疗费用(-180欧元 [95%CI -921至560])且未损失质量调整生命年(0.004 [95%CI -0.022至0.030])。
要点
- 患者发起随访联合异步远程医疗组1年内风湿科就诊次数平均1.9次,常规照护组2.6次,平均差-0.7(95%CI -1.0至-0.3),降低25.4%,p<0.0001。
- 从医疗保健角度具有成本效果,节省医疗费用-180欧元(95%CI -921至560),质量调整生命年变化0.004(95%CI -0.022至0.030)。
- 患者发起随访联合异步远程医疗组发生7例非试验相关不良事件,常规照护组8例(包括1例死亡)。
核心结论
- 患者发起随访联合异步远程医疗显著且具有临床意义地减少了风湿科就诊次数,未以健康结局为代价,并节省了医疗费用。
研究设计与样本
- TeleSpA为多中心、实用、开放标签、随机对照试验,纳入病情稳定的脊柱关节炎患者,1:1随机分配至患者发起随访联合异步远程医疗组或常规照护组。
- 所有患者在基线和1年后接受计划门诊访视;患者发起随访联合异步远程医疗组在6个月时远程监测,常规照护组由治疗风湿科医生酌情决定。
- 主要结局为1年内风湿科就诊次数;主要分析在意向治疗人群中进行;安全性分析基于不良事件和严重不良事件的自发报告或研究团队观察。
- 共200例患者随机分配(患者发起随访联合异步远程医疗组n=100,常规照护组n=100),其中女性79例(40%),男性121例(60%),平均年龄55.0岁(SD 11.9)。
- 试验注册于荷兰国家试验登记处(NL71041.068.19)和ClinicalTrials.gov(NCT04673825),已完成。
主要发现
- 1年后,患者发起随访联合异步远程医疗组平均风湿科就诊次数为1.9次(SD 1.5),常规照护组为2.6次(SD 1.3),平均差-0.7(95%CI -1.0至-0.3),降低25.4%,p<0.0001。
- 从医疗保健角度具有成本效果,节省医疗费用-180欧元(95%CI -921至560),质量调整生命年变化0.004(95%CI -0.022至0.030)。
- 患者发起随访联合异步远程医疗组发生7例非试验相关不良事件,常规照护组发生8例(包括1例死亡)。
关键数值与推荐
- 主要结局:1年内风湿科就诊次数,患者发起随访联合异步远程医疗组1.9次(SD 1.5) vs 常规照护组2.6次(SD 1.3),平均差-0.7(95%CI -1.0至-0.3),降低25.4%,p<0.0001。
- 成本效果:从医疗保健角度节省医疗费用-180欧元(95%CI -921至560),质量调整生命年变化0.004(95%CI -0.022至0.030)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With rising health-care expenditures and workforce shortages, sustainable alternatives to traditional outpatient follow-up strategies are required to optimise care efficiency. We aimed to investigate the cost-effectiveness and clinical effectiveness of patient-initiated follow-up (PIFU) supported by asynchronous telemedicine for patients with spondyloarthritis compared with usual care in daily practice. METHODS: TeleSpA was a multicentre, pragmatic, open-label, randomised controlled trial. Patients with spondyloarthritis and stable disease were randomly assigned (1:1) to either the PIFU and asynchronous telemedicine group or usual care group. All patients received a scheduled outpatient visit at baseline and after 1 year. Patients were monitored remotely at 6 months (PIFU and asynchronous telemedicine) or at the discretion of the treating rheumatologist (usual care). The primary outcome was the number of rheumatology visits within a 1-year period. A trial-based 1-year health-economic evaluation from a Dutch health-care perspective (only including health-care costs) and societal perspective (also including travel costs and work productivity losses), per the Dutch guidelines was used to estimate cost-effectiveness. The safety analysis was done in the intention-to-treat population and was based on spontaneous reports of adverse events and serious adverse events or as observed by the research team. The primary analysis was in the intention-to-treat population. Individuals with relevant lived experience were involved in the study design. This trial was registered with the Dutch National Trial Register (NL71041.068.19) and ClinicalTrials.gov (NCT04673825) and is completed. FINDINGS: Between Dec 2, 2020, and June 20, 2022, 200 patients were randomly assigned to PIFU and asynchronous telemedicine (n=100) or usual care (n=100). 79 (40%) of 200 participants were women, 121 (60%) were men, and the mean age was 55·0 years (SD 11·9). After 1 year, the mean number of rheumatology visits was 1·9 (SD 1·5) for the PIFU and asynchronous telemedicine group and 2·6 (1·3) in the usual care group (mean difference -0·7 [95% CI -1·0 to -0·3]; 25·4% reduction; p<0·0001). PIFU and asynchronous telemedicine was cost-effective from a health-care perspective, saving health-care costs (-€180 [95% CI -921 to 560]) without a loss in quality-adjusted life-years (0·004 [95 % CI -0·022 to 0·030]). Seven non-trial-related adverse events occurred in the PIFU and asynchronous telemedicine group and eight in usual care group (including one death). INTERPRETATION: PIFU and asynchronous telemedicine resulted in significant and clinically meaningful reductions in rheumatology visits. This was not at the expense of health outcomes and saved health-care costs. FUNDING: Dutch Arthritis Society.
引用
- Hermans K, Webers C, Boonen A, et al. Patient-initiated follow-up supported by asynchronous telemedicine versus usual care in spondyloarthritis (TeleSpA-study): a randomised controlled trial of clinical and cost-effectiveness. Lancet Rheumatol. 2024. PMID: 39492125. doi:10.1016/S2665-9913(24)00229-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。